TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2887328

Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cetirizine, 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cetirizine, 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29877199

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)-mobilized PBMNC transplantation combined with standard of care (SOC)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard of care (SOC) only
Number of subjects: 107
Study: 26477842

Group type: COMPARATOR
Intervention: Bevacizumab (Avastin) 1.25 mg
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis) 0.5 mg
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 441
Study: 24491074

Group type: EXPERIMENTAL
Intervention: RAP-PIR
Number of subjects: 0

Group type: COMPARATOR
Intervention: RAP-placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assessment-only waiting-list control
Number of subjects: 0
Study: 23848427

Group type: EXPERIMENTAL
Intervention: IPS + TAU
Number of subjects: 146

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 146
Study: 20224475

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (0.625 mg)
Number of subjects: 7
Study: 18160813

Group type: EXPERIMENTAL
Intervention: Mouthrinse with 0.2% NaF solution
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Toothpicks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Brushing with toothpaste containing 0.32% fluoride
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flossing combined with brushing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gels (0.2% or 0.32%) alone and in combination with brushing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Interdental brush with fluoride gel after toothbrushing
Number of subjects: 10
Study: 20622758

Group type: EXPERIMENTAL
Intervention: Circumcision
Number of subjects: 3
Study: 15786539

Group type: COMPARATOR
Intervention: Triple therapy with rabeprazole (10 mg twice daily), clarithromycin (200 mg twice daily) and amoxicillin (750 mg twice daily)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Sofalcone (100 mg thrice daily) plus the triple therapy
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Polaprezinc (150 mg twice daily) plus the triple therapy
Number of subjects: 165
Study: 11389501

Group type: EXPERIMENTAL
Intervention: New antifungal agents (specific agents not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical control comparisons
Number of subjects: 0
Study: 9159561

Group type: EXPERIMENTAL
Intervention: 600 mg rifampicin once daily for 5 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7862817

Group type: EXPERIMENTAL
Intervention: Intravenous benztropine (2 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Propranolol (1 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 5
Study: 3655310

Group type: EXPERIMENTAL
Intervention: 12-week intramuscular lymphoblastoid interferon treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 24-week intramuscular lymphoblastoid interferon treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 40
Study: 11903319

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 20
Study: 31304593

Group type: EXPERIMENTAL
Intervention: 400 μg rectal misoprostol at urinary catheter insertion plus 400 μg rectally after abdominal closure (preoperative group, n=100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 800 μg of rectal misoprostol after abdominal closure (postoperative group, n=100)
Number of subjects: 200
Study: 28914260

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (Hd‐MTX) therapy (3 g/m2)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Intermediate-dose methotrexate (Id‐MTX) therapy (0.5 g/m2)
Number of subjects: 360
Study: 26972745

Group type: EXPERIMENTAL
Intervention: Naltrexone (NAL)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Naltrexone (NAL) and prolonged exposure (PE)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 165

Group type: COMPARATOR
Intervention: Pill placebo and PE
Number of subjects: 165
Study: 24642289

Group type: EXPERIMENTAL
Intervention: L-Dopa (150 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21611728

Group type: EXPERIMENTAL
Intervention: Dynamically mixed Impregum Penta H DuoSoft (DMM)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Statically mixed Impregum Soft tray material (SAM)
Number of subjects: 290
Study: 20621900

Group type: EXPERIMENTAL
Intervention: Enoxaparin, 40 mg/d subcutaneously for 28 +/- 4 days after receiving open-label enoxaparin for an initial 10 +/- 4 days.
Number of subjects: 5963

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5963
Study: 17442265

Group type: COMPARATOR
Intervention: Exposure with response prevention (ERP) in therapist's office
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Exposure with response prevention (ERP) in natural environments (home, work, public places, car)
Number of subjects: 28
Study: 16351767

Group type: EXPERIMENTAL
Intervention: Olive oil-based intravenous lipid emulsion (ILE)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Soyabean oil-based intravenous lipid emulsion (ILE)
Number of subjects: 13
Study: 11942872

Group type: EXPERIMENTAL
Intervention: EMLA cream (Group E)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo cream (Group P)
Number of subjects: 81
Study: 9796928

Group type: EXPERIMENTAL
Intervention: 1000 units BtxA (Dysport) + electrical stimulation (A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1000 units BtxA (B)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo + electrical stimulation (C)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (D)
Number of subjects: 24
Study: 7658778

Group type: EXPERIMENTAL
Intervention: Improved STD case management in intervention communities
Number of subjects: 12537

Group type: COMPARATOR
Intervention: Standard care in comparison communities
Number of subjects: 12537

Group type: COMPARATOR
Intervention: Overall comparison of HIV incidence
Number of subjects: 12537
Study: 2698567

Group type: EXPERIMENTAL
Intervention: Gallopamil (3 X 50 mg daily for 4 weeks)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (1 week prior to gallopamil)
Number of subjects: 6
Study: 1093651

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (trimethoprim, 80 mg and sulfamethoxazole, 400 mg) - single dose
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (trimethoprim, 80 mg and sulfamethoxazole, 400 mg) - two doses
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: TMP-SDZ (sulfadiazine, 400 mg and trimethoprim, 80 mg) - single dose
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: TMP-SDZ (sulfadiazine, 400 mg and trimethoprim, 80 mg) - two doses
Number of subjects: 184
Study: 30239450

Group type: EXPERIMENTAL
Intervention: 8-week biweekly lower-limb elastic band training (knee and hip extension)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 29151102

Group type: EXPERIMENTAL
Intervention: Calcium, Vitamin D, and Genistein supplementation
Number of subjects: 102

Group type: COMPARATOR
Intervention: Calcium and Vitamin D supplementation
Number of subjects: 102
Study: 25272194

Group type: EXPERIMENTAL
Intervention: Maximum ARB dose
Number of subjects: 200

Group type: COMPARATOR
Intervention: Losartan 50 mg/hydrochlorothiazide 12.5 mg combination
Number of subjects: 200
Study: 23188089

Group type: EXPERIMENTAL
Intervention: RULER Approach integrated into fifth- and sixth-grade English language arts classrooms
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard ELA curriculum only (comparison schools)
Number of subjects: 62
Study: 21665552

Group type: EXPERIMENTAL
Intervention: Vibration applied to the segmentally related site during assessment of PPTs
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercised leg (DOMS affected)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control leg (contralateral leg)
Number of subjects: 16
Study: 19471949

Group type: COMPARATOR
Intervention: IV siplizumab (0.012 mg/kg and 0.04 mg/kg) given every 2 weeks for 8 doses
Number of subjects: 544

Group type: COMPARATOR
Intervention: SC siplizumab (5 mg for 12 weeks, 5 mg for 6 weeks, and 7 mg for 4 weeks)
Number of subjects: 544

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study: 16505664

Group type: EXPERIMENTAL
Intervention: Sequential gas delivery (SGD) mask at 8 L/min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nonrebreathing mask (NRM)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Venturi oxygen mask
Number of subjects: 8
Study: 12867391

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% given every evening
Number of subjects: 34

Group type: COMPARATOR
Intervention: Timolol 0.5% and dorzolamide 2% fixed combination (TDFC) given twice daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Timolol 0.5% and dorzolamide 2% fixed combination (TDFC) at 10:00 PM
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% at 10:00 PM
Number of subjects: 34

Group type: COMPARATOR
Intervention: Timolol 0.5% and dorzolamide 2% fixed combination (TDFC)
Number of subjects: 34
Study: 10550446

Group type: EXPERIMENTAL
Intervention: hPTH (1-34) 50 units weekly (L group)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: hPTH (1-34) 100 units weekly (M group)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: hPTH (1-34) 200 units weekly (H group)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: All groups (L, M, H)
Number of subjects: 220
Study: 9076650

Group type: EXPERIMENTAL
Intervention: Center for Addiction and Pregnancy (CAP) model of care
Number of subjects: 100

Group type: COMPARATOR
Intervention: CAP participants
Number of subjects: 100
Study: 1680123

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Quazepam 15 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 6614422

Group type: EXPERIMENTAL
Intervention: 0.15 mg buprenorphine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.3 mg buprenorphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 4 mg morphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Buprenorphine (both doses)
Number of subjects: 40
Study: 30811881

Group type: COMPARATOR
Intervention: CE (finger shapes) technique
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: LASOO (Lift, Apply, Slide, Oppose, Observe) technique
Number of subjects: 76
Study: 30964968

Group type: EXPERIMENTAL
Intervention: Philips Sonicare EasyClean power toothbrush with InterCare brush head and AirFloss Pro powered device, used with BreathRx mouthrinse for interdental cleaning (Sonicare Orthodontic Regimen or SOR)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Manual toothbrush plus string floss (MTF regimen)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Philips Sonicare EasyClean power toothbrush with InterCare brush head and AirFloss Pro powered device, used with BreathRx mouthrinse for interdental cleaning (SOR)
Number of subjects: 223
Study: 28558061

Group type: EXPERIMENTAL
Intervention: Low dose antimony
Number of subjects: 72

Group type: COMPARATOR
Intervention: High dose antimony
Number of subjects: 72
Study: 26775868

Group type: EXPERIMENTAL
Intervention: Nutritional drink (Fresubin Energy®)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Co-administration of SNEDDS with conventional cinnarizine tablet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 10
Study: 25042311

Group type: EXPERIMENTAL
Intervention: Facilitatory taping
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inhibitory taping
Number of subjects: 24
Study: 21929736

Group type: EXPERIMENTAL
Intervention: Telmisartan (40-80 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Amlodipine (5-10 mg daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 20

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 20
Study: 19537366

Group type: EXPERIMENTAL
Intervention: BoNT‐A (50 units)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 17468653

Group type: EXPERIMENTAL
Intervention: Xylitol (9.6 g daily, 3 times a day)
Number of subjects: 663

Group type: COMPARATOR
Intervention: Control product (0.5 g daily, 3 times a day)
Number of subjects: 663

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Xylitol
Number of subjects: 663
Study: 15826231

Group type: EXPERIMENTAL
Intervention: Practice (increased exposure to tasks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metacontrast masked primes (used to avoid conscious strategy changes)
Number of subjects: 0
Study: 12324304

Group type: EXPERIMENTAL
Intervention: Dietary intakes of beta-carotene, alpha-carotene, beta-cryptoxanthin, lycopene, and lutein + zeaxanthin
Number of subjects: 1452

Group type: COMPARATOR
Intervention: Subcohort of 5,681 women (noncases)
Number of subjects: 1452
Study: 9778325

Group type: EXPERIMENTAL
Intervention: 30000 IU heparin with 10.5 g SNAC
Number of subjects: 0

Group type: COMPARATOR
Intervention: 30000 IU heparin alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10.5 g SNAC alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.25 g SNAC with heparin 30000 to 150000 IU
Number of subjects: 0
Study: 8160257

Group type: EXPERIMENTAL
Intervention: FPIA PF-stimulated saliva (CS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ARIS CA-stimulated saliva (CS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: FPIA CS
Number of subjects: 50

Group type: COMPARATOR
Intervention: ARIS CS
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PF-stimulated CS
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CA-stimulated CS
Number of subjects: 50
Study: 3277664

Group type: EXPERIMENTAL
Intervention: Topical carteolol 2%
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30927032

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27893955

Group type: COMPARATOR
Intervention: Methylphenidate (MPH) high dose
Number of subjects: 60

Group type: COMPARATOR
Intervention: Methylphenidate (MPH) medium dose
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 60
Study: 25925415

Group type: EXPERIMENTAL
Intervention: Moderate wine consumption (at least 1 glass per day)
Number of subjects: 6973

Group type: COMPARATOR
Intervention: No significant difference in clinical outcomes
Number of subjects: 6973
Study: 23433723

Group type: EXPERIMENTAL
Intervention: Family-led mutual support group
Number of subjects: 135

Group type: COMPARATOR
Intervention: Psycho-education group
Number of subjects: 135

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 135
Study: 21463064

Group type: EXPERIMENTAL
Intervention: Objective memory performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived frequency of forgetting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of external aids (calendars, reminder notes)
Number of subjects: 0
Study: 18990531

Group type: EXPERIMENTAL
Intervention: Intravenous tigecycline
Number of subjects: 418

Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 418
Study: 17245175

Group type: EXPERIMENTAL
Intervention: Tissucol fibrin glue
Number of subjects: 197

Group type: COMPARATOR
Intervention: staples
Number of subjects: 197
Study: 15133007

Group type: EXPERIMENTAL
Intervention: 7% hyperoxic CO2
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 5% hyperoxic CO2
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CO2 (5% and 7%)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CO2 (7%)
Number of subjects: 13
Study: 11769782

Group type: EXPERIMENTAL
Intervention: Interventions to correct refractive errors and cataract surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study: 9233110

Group type: EXPERIMENTAL
Intervention: Granisetron 10 micrograms/kg IV
Number of subjects: 54

Group type: COMPARATOR
Intervention: Saline solution IV
Number of subjects: 54
Study: 7967102

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (quantity in g/week and frequency in times/week)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (15 <= cigarette/day < 25)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Frequent intake of fruit
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: High-temperature food and drink preference
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Shochu consumption
Number of subjects: 141
Study: 12318275

Group type: EXPERIMENTAL
Intervention: Soft silicone rubber uterine probe with reading scale
Number of subjects: 1000
Study: 2502065

Group type: EXPERIMENTAL
Intervention: Fleroxacin 200 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Fleroxacin (200 or 400 mg)
Number of subjects: 53
Study: 31730088

Group type: EXPERIMENTAL
Intervention: Interferometry-free noncontact photoacoustic detection method based on speckle correlation change
Number of subjects: 0
Study: 28328159

Group type: EXPERIMENTAL
Intervention: fosdagrocorat 10 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: fosdagrocorat 25 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: prednisone 5 mg
Number of subjects: 86

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 86
Study: 25754254

Group type: EXPERIMENTAL
Intervention: Music group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 24402015

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 117

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 117
Study: 21983008

Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT)
Number of subjects: 27347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27347

Group type: EXPERIMENTAL
Intervention: Baseline sexual activity
Number of subjects: 27347

Group type: EXPERIMENTAL
Intervention: Vaginal atrophy
Number of subjects: 27347

Group type: EXPERIMENTAL
Intervention: Demographic and health characteristics
Number of subjects: 27347
Study: 19755817

Group type: EXPERIMENTAL
Intervention: Hange-shashin-to
Number of subjects: 20

Group type: COMPARATOR
Intervention: S-1/Irinotecan (CPT-11) therapy
Number of subjects: 20
Study: 16752738

Group type: EXPERIMENTAL
Intervention: Physiotherapy added to rehabilitation complex
Number of subjects: 120

Group type: COMPARATOR
Intervention: Drugs and physiotherapeutic factors
Number of subjects: 120
Study: 15315558

Group type: EXPERIMENTAL
Intervention: TransCyte
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Biobrane
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Silvazine
Number of subjects: 33
Study: 11242223

Group type: EXPERIMENTAL
Intervention: Preoperative MRI
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Postoperative MRI
Number of subjects: 51

Group type: COMPARATOR
Intervention: Neurologic examination
Number of subjects: 51
Study: 9323940

Group type: EXPERIMENTAL
Intervention: carteolol hydrochloride 1%
Number of subjects: 176

Group type: COMPARATOR
Intervention: timolol maleate 0.5%
Number of subjects: 176
Study: 7954035

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg starting dose, increased to 8 mg if DBP > 95 mmHg)
Number of subjects: 47351

Group type: EXPERIMENTAL
Intervention: Perindopril alone
Number of subjects: 47351

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg dose)
Number of subjects: 47351

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 47351

Group type: EXPERIMENTAL
Intervention: Cough (adverse event)
Number of subjects: 47351

Group type: EXPERIMENTAL
Intervention: Fatal outcomes
Number of subjects: 47351
Study: 3579820

Group type: EXPERIMENTAL
Intervention: Atropine 2.0 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atropine 4.0 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atropine (0.5, 1.0, 2.0, 4.0 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atropine 2.0 mg and 4.0 mg
Number of subjects: 20
Study: 30145102

Group type: EXPERIMENTAL
Intervention: 14-day bismuth-containing quadruple therapy (group A)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Quadruple therapy supplemented with Clostridium butyricum (group B)
Number of subjects: 105

Group type: COMPARATOR
Intervention: H. pylori-negative patients (group C)
Number of subjects: 105
Study: 26855568

Group type: EXPERIMENTAL
Intervention: Group B patients (COPD GOLD Group B)
Number of subjects: 17135

Group type: EXPERIMENTAL
Intervention: Group D patients (COPD GOLD Group D)
Number of subjects: 17135

Group type: EXPERIMENTAL
Intervention: Groups A-D (COPD GOLD Groups A-D)
Number of subjects: 17135
Study: 25075999

Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing (DB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pilates breathing (PB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Natural breathing (NB)
Number of subjects: 30
Study: 23077047

Group type: EXPERIMENTAL
Intervention: Binary feedback after initial adaptation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visuomotor rotation with error-clamp condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both binary feedback and vector error present
Number of subjects: 0
Study: 20093548

Group type: EXPERIMENTAL
Intervention: Apligraf (Organogenesis, Inc) used in conjunction with standard therapy (sharp debridement, standard wound care, and off-loading)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 72
Study: 17538514

Group type: EXPERIMENTAL
Intervention: Letter + test‐request card for a CT urine home sampling kit (arm 1, n = 2940)
Number of subjects: 8820

Group type: EXPERIMENTAL
Intervention: Letter + mail‐back sampling kit (arm 2, n = 2940)
Number of subjects: 8820

Group type: COMPARATOR
Intervention: Usual care control (arm 3, n = 2940)
Number of subjects: 8820
Study: 16286173

Group type: EXPERIMENTAL
Intervention: High-phenolic virgin olive oil breakfast
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low-phenolic virgin olive oil breakfast
Number of subjects: 21